[Drug Price Reform Fallout] ③Unclear Preferential Criteria Disrupt Business Planning
All-Out Efforts to Protect Profitability Ahead of Next Month's Drug Price Reform
Uncertainty Remains over Timing of Innovative Pharmaceutical Company Certification
Success Hinges on Precision of Follow-Up Criteria
① Shaken Laboratories, Departing Talent
② 'On Fire' Pharmaceutical Companies Struggling with 'Product Portfolio Diet'
③ Unclear Preferential Criteria Disrupt Business Planning
With about one month left until the implementation of the generic drug price reform, pharmaceutical companies remain anxious, unable to finalize their business plans for the second half of the year. Although generic drug prices will decrease, the preferential criteria for innovative and quasi-innovative pharmaceutical companies, essential and market-retention drugs, and items with localized raw materials have yet to be finalized, further fueling confusion.
According to industry sources on July 1, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association has formed task forces (TFTs) for each field—including revised pricing criteria, essential and market-retention drugs, active pharmaceutical ingredients, innovative and quasi-innovative companies, and new drugs—to discuss follow-up standards with the Ministry of Health and Welfare. The government intends to reduce competition over the number of generic items and favor companies with strong R&D capabilities and supply capacity for essential drugs. However, after the drug price reform, each company’s profit and loss will depend on item-by-item pricing criteria and the timing of special provisions. This is why companies manufacturing combination drugs, drugs that require data submission, and extended-release formulations are paying close attention to the upcoming detailed criteria.
Confusion Over Standards for Combination Drugs and Essential Medicines
Combination drugs and extended-release formulations incur higher development and regulatory documentation costs than standard generics. Clinical or bioequivalence study design, quality documentation, and production process validation are also more expensive. If these cost differences are not adequately reflected in drug price calculations, companies will have less incentive to invest in upgrading generics to improved new drugs.
The scope of supply-stabilizing drugs is also at issue. The government plans to designate companies with a high proportion of national essential or market-retention drugs as leaders in supply stability and grant them preferential drug prices. Drugs that require local production of raw materials or maintenance of manufacturing capacity are also included as separate preferential categories. However, the follow-up criteria will determine the extent to which domestic raw material use is recognized, how direct and contract manufacturing are distinguished, and what benchmarks are set for supply ratio. An industry source said, “Even if a company manufactures national essential medicines, many items are difficult to handle due to fluctuations in raw material prices and production volume. If the criteria for supply stability leaders do not reflect the actual cost structures on the ground, it will be difficult to increase production despite preferential measures.”
Delayed Certification Means Delayed Investment
The timing of preferential treatment for innovative and quasi-innovative pharmaceutical companies is also a variable. The government plans to guarantee up to a 60% price premium for up to four years for innovative pharmaceutical companies, and up to a 50% premium for up to four years for newly designated quasi-innovative companies. The plan also includes temporary special provisions for innovative and quasi-innovative companies during the price adjustment process for existing medicines. This is why mid-tier and larger pharmaceutical companies are strengthening their R&D, regulatory affairs, and quality management organizations.
The problem is that there could be a gap between the implementation of the system and the timing of certification and preferential treatment. The government has announced plans to revise and announce the pricing criteria for adjusting registered drugs and to begin adjustments in the second half of the year. However, the industry expects that even if companies prepare for the innovative or quasi-innovative track now, the certification results may only be available around October or November. In this case, companies will have to finalize their second-half R&D budgets and staffing plans without knowing whether they will receive preferential treatment. An executive at a mid-sized pharmaceutical company said, “If the certification timing and drug price application timing do not align, it will be difficult to increase investment immediately.”
Now that the extent of the generic drug price cuts has been determined, the success of the price reform hinges on how meticulously the follow-up criteria are established. For the intended purpose of reducing excessive competition in generics and favoring R&D-oriented companies to be achieved, companies need a buffer mechanism to allow them to adapt to the new standards. There are also calls for clear, separate pricing standards for high-development-cost products such as combination drugs and data-submission medicines, and for narrowing the gap between certification and drug price application for innovative and quasi-innovative companies.
There are also calls for different support measures for small pharmaceutical companies. Preferential pricing alone will not be enough to turn generic-focused companies into R&D-driven enterprises. Consulting and R&D support for clinical trial design, quality documentation, and regulatory strategy development should be provided together. An industry insider said, “If the government has created frameworks like quasi-innovative and supply-stability leader companies, it should give companies enough time to prepare for those standards.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.